M&A and Strategic Deals: Thermo Fisher, BD, and Quest Use M&A to Advance Post-COVID-19 Strategies
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
After an eventful month in the Illumina-GRAIL saga, the story may soon be over.
G2 Intelligence’s June 13-14 virtual event offers expert advice to help labs navigate today’s economic challenges.
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
This panel will help laboratory owners make decisions now to be better positioned in the future for a potential sale.